HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su

Rhea-AI Filing Summary

HUTCHMED (China) Limited reports the vesting of non-performance based awards under its Long Term Incentive Plan. On March 13, 2026, awards granted on March 13, 2024 to Dr. Weiguo Su, Executive Director, Chief Executive Officer and Chief Scientific Officer, vested into 19,913 ordinary shares.

The vesting occurred at a price of nil and outside a trading venue, reflecting equity-based compensation rather than a market transaction. The notification is made in line with UK Market Abuse Regulation requirements and relates to ordinary shares of US$0.10 par value.

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of March 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Announcement relating to vesting of awards under the long term incentive plan
​	​	​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: March 16, 2026

3

​

Exhibit 99.1

​

​

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Monday, March 16, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 13, 2026:-

​

	​
Award Holder	​	Number of ordinary shares
​	​	​
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	​	19,913

​

The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.

​

​

​

​

Dr Weiguo Su

​

​

​ ​	​ ​	​ ​
1	Details of the person discharging managerial responsibilities/person closely associated
​ a)	​ Name	​ Dr Weiguo Su
2	Reason for the notification
​ a)	​ Position/status	​ Executive Director, Chief Executive Officer and Chief Scientific Officer
​ b)	​ Initial notification/Amendment	​ Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
​ a)	​ Name	​ HUTCHMED (China) Limited
​ b)	​ LEI	​ 2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
​ a)	​ Description of the financial instrument, type of instrument ​ Identification code	​ Ordinary Shares of US$0.10 ​ ​ Ordinary Share with DI ISIN: KYG4672N1016
​ b)	​ Nature of the transaction	​ Vesting of awards granted on March 13, 2024 under HUTCHMED's LTIP
​ c)	​ Price(s) and volume(s)	​	​	​	​
		​	​	​	Price(s)	Volume(s)	​
		​	​	​	Nil	19,913 ordinary shares	​
		​	​	​	​	​	​
​ d)	​ Aggregated information — Aggregated volume — Price​	​ N/A
​ e)	​ Date of the transaction	​ 2026-03-13
​ f)	​ Place of the transaction	​ Outside a trading venue

​

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

​

​

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
	​
Media Enquiries	​
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
	​
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
	​
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
	​
Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	+44 20 7260 1000

​

FAQ

What did HUTCHMED (HCM) disclose in this Form 6-K filing?

HUTCHMED disclosed the vesting of non-performance based awards under its Long Term Incentive Plan. On March 13, 2026, these awards converted into 19,913 ordinary shares for CEO Dr. Weiguo Su as part of his compensation.

How many HUTCHMED (HCM) shares vested for Dr. Weiguo Su?

A total of 19,913 HUTCHMED ordinary shares vested for Dr. Weiguo Su. These shares relate to non-performance based awards granted on March 13, 2024 under the company’s Long Term Incentive Plan and vested on March 13, 2026.

What is the nature of the HUTCHMED (HCM) transaction reported?

The transaction is the vesting of share awards under HUTCHMED’s Long Term Incentive Plan. It represents equity compensation, not a market trade, with 19,913 ordinary shares vesting at a nil price outside a trading venue for Dr. Weiguo Su.

At what price did the HUTCHMED (HCM) LTIP awards vest?

The Long Term Incentive Plan awards vested at a price of nil. This confirms the shares were delivered as compensation rather than purchased on the market, aligning with typical equity award vesting structures for senior executives.

When were the HUTCHMED (HCM) LTIP awards granted and when did they vest?

The non-performance based LTIP awards were granted on March 13, 2024 and vested on March 13, 2026. This two-year period reflects the vesting schedule for the 19,913 ordinary shares awarded to Dr. Weiguo Su under HUTCHMED’s plan.

Which regulations apply to this HUTCHMED (HCM) award vesting disclosure?

The disclosure is provided in accordance with UK Market Abuse Regulation requirements. HUTCHMED reports details of the person discharging managerial responsibilities, the award terms, and the vesting transaction for transparency to investors and regulators.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 47.2 KB